{"title": "Population based surveillance for laboratory confirmed influenza", "author_url": "http://www.tibdn.ca/author/admin", "html": "<p>\r\n\t<code>Status:&nbsp; Currently Recruiting</code></p>\r\n<h2>\r\n\tWhy are we doing this?</h2>\r\n<p>\r\n\tInfluenza remains the most common infectious disease causing death and hospitalization in the developed world.&nbsp; The advent of routine rapid testing for influenza, the availability of new drugs for its treatment, and the attention focused on viral respiratory illnesses&nbsp;have resulted in&nbsp; more diagnostic testing for respiratory viruses, and a new appreciation for the impact of&nbsp;influenza on both our health and use of health care resources.<br />\r\n\t<br />\r\n\tOur goal is to continue to provide clinicians in south-central Ontario with descriptions of the clinical features and outcomes of serious influenza-related illness in their population, and to determine whether there are laboratory, hospital or region specific differences in the use of influenza diagnostic tests and preventative and management strategies.</p>\r\n<h2>\r\n\tObjectives</h2>\r\n<ul>\r\n\t<li>\r\n\t\tTo describe the incidence, clinical features and outcomes of episodes of laboratory-confirmed influenza associated with hospitalization in a defined population and to assess variability in diagnosis and management</li>\r\n\t<li>\r\n\t\tTo conduct ongoing assessment of the effectiveness of influenza vaccination in preventing influenza-associated hospitalization and death&nbsp;&nbsp;</li>\r\n\t<li>\r\n\t\tTo characterize the burden of disease, clinical outcomes, and resource utilization&nbsp; associated with influenza A and influenza B lineages</li>\r\n\t<li>\r\n\t\tTo assess the effect of treatment with anti-viral medications on hospital length of stay and mortality</li>\r\n</ul>\r\n<h2>\r\n\tWho is being asked to participate?</h2>\r\n<ul>\r\n\t<li>\r\n\t\tAnyone admitted to a hospital&nbsp;and has had a respiratory sample (eg. nasal/pharyngeal swab, sputum) which has tested positive for influenza</li>\r\n</ul>\r\n<h2>\r\n\tIf I agree to participate, what will I need to do?</h2>\r\n<p>\r\n\tIf you agree to participate you will be consenting to:</p>\r\n<ul>\r\n\t<li>\r\n\t\tbeing interviewed for approximately 10-15 minutes about vaccination and possible risk factors for infection</li>\r\n\t<li>\r\n\t\tbeing called by the study nurse about 1 month after discharge from the hospital to see how you are recovering since your illness</li>\r\n\t<li>\r\n\t\tthe release of information about you medical history from the hospital</li>\r\n\t<li>\r\n\t\tthe release of information about previous vaccinations and antibiotics from your family doctor and/or vaccination clinic</li>\r\n\t<li>\r\n\t\thaving any left over specimen from your nose swab sent to the study laboratory for storage and possible future testing.</li>\r\n</ul>\r\n<h2>\r\n\tHow long will the study last?&nbsp;</h2>\r\n<p>\r\n\tThis study has been running since&nbsp;2004&nbsp;at all TIBDN hospitals (with the exception of the Hospital for Sick Children).&nbsp;We are currently enrolling for the 2012-2013 influenza season.</p>\r\n<h2>\r\n\tAre there any risks to participating in this study?</h2>\r\n<p>\r\n\tThere are no risks for you in taking part in this study. You are not being given any medication and no change in your treatment will result from your participation. You may find the interviews or questions upsetting or distressing or you may not like all of the questions that you are asked. You may refuse to answer questions or stop the interview at any time if you are uncomfortable. We take every precaution to protect your personal information. Any information and left-over test sample you provide to the study is confidential and is identified only by a study code number. No one will be able to identify the study information or sample as belonging to you.</p>\r\n<h2>\r\n\tWho can I contact if I am interested in the study?&nbsp;&nbsp;</h2>\r\n<p>\r\n\tCall the study office at Mount Sinai Hospital, 416-586-4800, ext. 2761 or 1-800-668-6292.</p>\r\n<p>\r\n\tYou will be directed to the TIBDN reseach personnel assigned to the hospital where you were admitted.</p>\r\n<h2>\r\n\tInvestigators</h2>\r\n<p>\r\n\t<a href=\"http://resolveuid/d8e0b63ee0d54efc96da6b201d29e5d8\">Dr. Allison McGeer</a>, Principal Investigator</p>\r\n<p>\r\n\t<code><a href=\"http://www.tibdn.ca/about/investigators\">Click here for full investigator list</a></code></p>\r\n<h2>\r\n\tFunding partner</h2>\r\n<p>\r\n\tThis work is funded through an Investigator-Initiated Research Grant provided by Hoffman LaRoche Ltd. The funding partner plays no role in the conduct of the protocol, the data collection, analysis or reporting of results.</p>\r\n<h2>\r\n\tEthics</h2>\r\n<p>\r\n\tThis study has been approved by the Research Ethics Boards at all participating hospitals.</p>\r\n<h2>\r\n\t<a href=\"http://www.tibdn.ca/about/participants\">Participating&nbsp;TIBDN Sites</a></h2>\r\n<p>\r\n\t&nbsp;</p>\r\n", "version": "1.0", "type": "rich", "provider_name": "TIBDN: Toronto Invasive Bacterial Diseases Network", "provider_url": "http://www.tibdn.ca", "author_name": ""}